A Phase 2 interventional study of AZD6234 and Placebo in Obesity/Overweight, sponsored by AstraZeneca. Active, not recruiting at 3 sites in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing AZD6234 in Obesity — 2 open to participants now, 4 under way, 1 of them phase 3. AZD6234 · Obesity.
Among the 10 studies testing AZD6234 in Obesity, this one is the 10th largest by enrollment, is one of 5 that started in 2025, is one of 4 in phase 2, and was the 6th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →2 of the 10 studies testing AZD6234 in Obesity are open now, in 3 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China, India
Ages 18+
AstraZeneca · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 5 started in 2025.
This study's enrollment of 16 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 85 across the 10 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
52 studies in Obesity by AstraZeneca: 8 open now, 12 under way, 5 of them phase 3. Of 40 finished, 9 (23%) have results posted.
Among the 52 studies in Obesity by AstraZeneca, this one is the 47th largest by enrollment of the 50 interventional ones that give a count, is one of 9 that started in 2025, is one of 18 in phase 2, reaches primary completion later than 0 of the 11 other live ones, and was the 39th registered.
AstraZeneca’s Obesity studies by the year they started, since 2004.
2 of the studies testing AZD6234 in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07911514AstraZenecaA Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 | 2027-05-04 |
| NCT07013643AstraZenecaA Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity | 2027-07-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing AZD6234 in Obesity, from their registry updates:
Among AstraZeneca’s 52 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.
This is a Phase Ⅱa, multi-centre, multi-drug, platform study in Chinese participants living with obesity/overweight. This platform study will consist of several sub-studies. Eligible participants will be allocated to one sub-study to receive the study intervention(s). Each sub-study will consist of a screening period, a treatment period, and a follow-up period.
Sub-study 1: AZD6234 Monotherapy This study will explore the safety, tolerability, pharmacokinetic (PK), efficacy, and immunogenicity of AZD6234 in Chinese participants with obesity/overweight, approximate 18 participants will be randomised in sub-study 1. The sub-study will comprise 3 periods totalling up to approximately 23 weeks.
Sub-study 2: AZD9550 Monotherapy and AZD6234 in combination with AZD9550 This study will explore the safety, tolerability, PK, efficacy, and immunogenicity of AZD9550 and of AZD6234 in combination with AZD9550 in Chinese participants with obesity/overweight, approximately 30 participants will be randomised in sub-study 2 (15 in Cohort A and 15 in Cohort B). The sub-study will comprise 3 periods totalling up to approximately 35 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Significant hepatic disease (except for non-alcoholic steatohepatitis or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening:
Uncontrolled thyroid disease, defined as TSH > ULN or \< LLN for the laboratory reference range, as judged by the PI at screening.
Sub-study 2 only
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous injection of AZD6234 on Day 1 and continue for 16 weeks.
Drug: AZD6234
Participants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 16 weeks.
Drug: Placebo
Participants will receive subcutaneous injection of AZD9550 on Day 1 and continue for 28 weeks.
Drug: AZD9550
Participants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 28 weeks.
Drug: Plocebo
Participants will receive subcutaneous injection of AZD6234 and AZD9550 on Day 1 and continue for 28 weeks.
Drug: AZD6234 in combination with AZD9550
Participants will receive subcutaneous injection of matched volume of placebo on Day 1 and continue for 28 weeks.
Drug: Placebo
Participants will receive a subcutaneous injection weekly
Participants will receive a subcutaneous injection weekly.
Participants will receive a subcutaneous injection weekly
Participants will receive a subcutaneous injection weekly
Participants will receive a subcutaneous injection weekly
Participants will receive a subcutaneous injection weekly
Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 1).
To assess the safety and tolerability of repeated subcutaneous(SC) doses of AZD6234 compared to placebo.
Time frame: From baseline to Day 141
Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 2).
To assess the safety and tolerability of repeated SC doses of AZD9550 and AZD6234 in combination with AZD9550 compared to placebo.
Time frame: From baseline to Day 225
PK parameters : Cmax (sub-study 1)
To characterise the PK of AZD6234 following repeated subcutaneous (SC) doses.
Time frame: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85,106,113,120,127,141 Pre-dose. Day 1,36,43,57,106 post-dose 2,4,8,12,24,36,48,60,72,96 hours.
PK parameters : Tmax (sub-study 1)
To characterise the PK of AZD6234 following repeated SC doses.
Time frame: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85,106,113,120,127,141 Pre-dose. Day 1,36,43,57,106 post-dose 2,4,8,12,24,36,48,60,72,96 hours.
PK parameters : AUClast (sub-study 1)
To characterise the PK of AZD6234 following repeated SC doses.
Time frame: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85,106,113,120,127,141 Pre-dose. Day 1,36,43,57,106 post-dose 2,4,8,12,24,36,48,60,72,96 hours.
PK parameters : AUCtau (sub-study 1)
To characterise the PK of AZD6234 following repeated SC doses.
Time frame: Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 85,106,113,120,127,141 Pre-dose. Day 1,36,43,57,106 post-dose 2,4,8,12,24,36,48,60,72,96 hours.
Percent change in body weight from baseline to Week 16 (sub-study 1)
To assess the effects of AZD6234 on the body weight change from baseline with and without placebo correction.
Time frame: From baseline to Week 16
Incidence of ADA to AZD6234 (sub-study 1).
To evaluate the immunogenicity of AZD6234 following repeated SC doses.
Time frame: Day 1 to Day 141
ADA titer of AZD6234 (sub-study 1).
To evaluate the immunogenicity of AZD6234 following repeated SC doses.
Time frame: Day 1 to Day 141
PK parameters : Cmax (sub-study 2 Cohort A)
To characterise the PK of AZD9550 following repeated SC doses.
Time frame: Days 1, 15, 29, 57, 85, 113, 141, 190, 204, 211, 225 per dose. Days 1, 57, 113, 141,190 post-dose 6, 12, 18, 24 hours (± 10 minutes). Day 190 post-dos 30, 36, 42, 48, 54, 60, 72, 96, 120, 144,168 hours (± 30 minutes).
PK parameters : Tmax (sub-study 2 Cohort A)
To characterise the PK of AZD9550 following repeated SC doses.
Time frame: Days 1, 15, 29, 57, 85, 113, 141, 190, 204, 211, 225 per dose. Days 1, 57, 113, 141,190 post-dose 6, 12, 18, 24 hours (± 10 minutes). Day 190 post-dos 30, 36, 42, 48, 54, 60, 72, 96, 120, 144,168 hours (± 30 minutes).
PK parameters : AUClast (sub-study 2 Cohort A)
To characterise the PK of AZD9550 following repeated SC doses.
Time frame: Days 1, 15, 29, 57, 85, 113, 141, 190, 204, 211, 225 per dose. Days 1, 57, 113, 141,190 post-dose 6, 12, 18, 24 hours (± 10 minutes). Day 190 post-dos 30, 36, 42, 48, 54, 60, 72, 96, 120, 144,168 hours (± 30 minutes).
PK parameters : AUCtau (sub-study 2 Cohort A)
To characterise the PK of AZD9550 following repeated SC doses.
Time frame: Days 1, 15, 29, 57, 85, 113, 141, 190, 204, 211, 225 per dose. Days 1, 57, 113, 141,190 post-dose 6, 12, 18, 24 hours (± 10 minutes). Day 190 post-dos 30, 36, 42, 48, 54, 60, 72, 96, 120, 144,168 hours (± 30 minutes).
Plasma trough concentration (sub-study 2 Cohort B).
To characterise the PK of AZD9550 and AZD6234 following repeated SC doses
Time frame: Day 1 to Day 225
Percent change in body weight from baseline to Week 28 (sub-study 2 ), placebo as comparator
To assess the effects of AZD9550 and AZD6234 in combination with AZD9550 on the body weight change from baseline with and without placebo correction.
Time frame: From baseline to Week 28
Percent change in body weight from baseline to Week 28 (sub-study 2, AZD9550 as comparator)
To assess the effects of AZD6234 in combination with AZD9550 compared to AZD9550 on the body weight change from baseline.
Time frame: From baseline to Week 28
Incidence of ADA to AZD9550 (sub-study 2).
To evaluate the immunogenicity of AZD9550 following repeated SC doses.
Time frame: Day 1 to Day 225
ADA titer of AZD9550 (sub-study 2 Cohort A).
To evaluate the immunogenicity of AZD9550 following repeated SC doses.
Time frame: Day 1 to Day 225
Incidence of ADA to AZD6234 and AZD9550 combination therapy (sub-study 2 Cohort B).
To evaluate the immunogenicity of AZD6234 and AZD9550 following repeated SC combination therapy doses.
Time frame: Day 1 to Day 225
ADA titer of AZD6234 and AZD9550 combination therapy (sub-study 2 Cohort B).
To evaluate the immunogenicity of AZD6234 and AZD9550 following repeated SC combination therapy doses.
Time frame: Day 1 to Day 225
Started May 2025 (actual). Primary completion is estimated for Oct 2026, 17 months after the start.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 17 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: AZD6234 · AZD9550